FDA Grants Accelerated Approval for New Advanced Melanoma Treatment

The FDA has granted accelerated approval to Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on prior anti-PD-1 therapy. This approval, based on objective response rate and duration of response from the Ignyte trial, provides a new second-line treatment option for patients facing a high unmet medical need, potentially improving outcomes for this aggressive cancer.